CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (NASDAQ: ZLCS) presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting in Berlin, Germany on November 18, 2010. In a poster presentation entitled “Identification of synergistic drugs using combination high-throughput screening (cHTS) and breadth of activity in diverse cancer cell networks,” Richard Rickles, Ph.D., Zalicus’s Director of Oncology Research demonstrated that systematic combination studies using the Zalicus combination high-throughput screening (cHTS) technology can reveal patterns of chemotherapeutic sensitivity and resistance to identify potentially responsive patient populations.
